Drug intelligence / Profile preview

[89Zr]Zr-DFO-RD06

Development stage: Unknown
Lead developer: Renji Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**[89Zr]Zr-DFO-RD06** is an investigational CD70-targeted immunoPET radiopharmaceutical developed by Renji Hospital. It consists of the CD70-binding antibody RD06 conjugated to the chelator desferrioxamine and labeled with the positron-emitting radionuclide zirconium-89. The agent is intended for PET/CT visualization of CD70-expressing malignancies rather than for therapeutic irradiation. It is being evaluated in a registered phase II imaging study in malignant cancers, including renal cell carcinoma, clear cell renal cell carcinoma, lymphoma, and nasopharyngeal carcinoma.

Other names: 89Zr-DFO-RD06

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on [89Zr]Zr-DFO-RD06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [89Zr]Zr-DFO-RD06.

Explore the full profile